# A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

> **NCT06039449** · PHASE3 · COMPLETED · sponsor: **Invivyd, Inc.** · enrollment: 790 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2

## Interventions

- **DRUG:** VYD222 (pemivibart)
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT06039449
- **Lead sponsor:** Invivyd, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-08
- **Primary completion:** 2024-11-19
- **Final completion:** 2024-11-19
- **Target enrollment:** 790 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06039449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06039449, "A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06039449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*